DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a ...

Verzenio (abemaciclib) is a brand-name oral tablet prescribed for certain forms of breast cancer. Verzenio has interactions with certain other drugs, some foods, and certain supplements.

One of those is taking Verzenio, a daily pill “to treat adults with HR+ [and] HER2,” its maker, Eli Lilly & Company, explains ...

Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a ...

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

Verzenio (abemaciclib) has just gained its first approval in HR+/HER2- metastatic breast cancer, but the failure in non-small cell lung cancer (NSCLC) limits the drug's growth options.

The pharmaceutical company is expected to benefit from blockbuster products like Verzenio in oncology, Ebglyss in immunology, and Kisunla, which was approved to treat Alzheimer's disease in July 2024.

Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...